← Back to patent-cliff list
CAS 1089192-62-0
Codes：ROMI-031
Application context (from source-drug indications)
外周T细胞淋巴瘤罗米地辛淋巴瘤罗米地辛嗜铬细胞瘤罗米地辛皮肤T细胞淋巴瘤罗米地辛非霍奇金淋巴瘤罗米地辛黑色素瘤罗米地辛
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 罗米地辛Romidepsin | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(R,E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid→ROMI-028→ROMI-029→ROMI-030→ROMI-031→ROMI-032→((Z)-2-((S)-2-((R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-3-(tritylthio)propanamido)but-2-enoyl)-L-valine→ROMI-034→ROMI-035→(S,E)-3-hydroxy-1-((R)-4-isopropyl-2-thioxothiazolidin-3-yl)-7-(tritylthio)hept-4-en-1-one
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.